PL2220214T3 - Sposób zwiększania immunoreaktywności - Google Patents

Sposób zwiększania immunoreaktywności

Info

Publication number
PL2220214T3
PL2220214T3 PL08860440T PL08860440T PL2220214T3 PL 2220214 T3 PL2220214 T3 PL 2220214T3 PL 08860440 T PL08860440 T PL 08860440T PL 08860440 T PL08860440 T PL 08860440T PL 2220214 T3 PL2220214 T3 PL 2220214T3
Authority
PL
Poland
Prior art keywords
immunoreactivity
increasing
increasing immunoreactivity
Prior art date
Application number
PL08860440T
Other languages
English (en)
Inventor
Gottfried Baier
Hans Loibner
Manfred Schuster
Günther LAMETSCHWANDTNER
Dominik Wolf
Original Assignee
Medizinische Universität Innsbruck
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universität Innsbruck, Apeiron Biologics Ag filed Critical Medizinische Universität Innsbruck
Publication of PL2220214T3 publication Critical patent/PL2220214T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL08860440T 2007-12-10 2008-12-10 Sposób zwiększania immunoreaktywności PL2220214T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0199607A AT506041A1 (de) 2007-12-10 2007-12-10 Verfahren zur erhöhung der immunreaktivität
EP08860440.0A EP2220214B1 (de) 2007-12-10 2008-12-10 Verfahren zur erhöhung der immunreaktivität
PCT/AT2008/000443 WO2009073905A2 (de) 2007-12-10 2008-12-10 Verfahren zur erhöhung der immunreaktivität

Publications (1)

Publication Number Publication Date
PL2220214T3 true PL2220214T3 (pl) 2018-07-31

Family

ID=40585504

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08860440T PL2220214T3 (pl) 2007-12-10 2008-12-10 Sposób zwiększania immunoreaktywności

Country Status (25)

Country Link
US (1) US8809288B2 (pl)
EP (2) EP2220214B1 (pl)
JP (2) JP6118491B2 (pl)
KR (1) KR101692797B1 (pl)
CN (2) CN101918544B (pl)
AT (1) AT506041A1 (pl)
AU (1) AU2008336276C1 (pl)
BR (1) BRPI0821003B8 (pl)
CA (1) CA2708343C (pl)
CY (1) CY1120136T1 (pl)
DK (1) DK2220214T3 (pl)
EA (1) EA018966B1 (pl)
ES (1) ES2665928T3 (pl)
HR (1) HRP20180558T1 (pl)
HU (1) HUE037235T2 (pl)
IL (1) IL206155A (pl)
LT (1) LT2220214T (pl)
MX (1) MX2010006296A (pl)
NZ (1) NZ585646A (pl)
PL (1) PL2220214T3 (pl)
PT (1) PT2220214T (pl)
RS (1) RS56941B1 (pl)
SI (1) SI2220214T1 (pl)
WO (1) WO2009073905A2 (pl)
ZA (1) ZA201003791B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566502T3 (es) 2006-09-13 2016-04-13 The Trustees Of Columbia University In The City Of New York Agentes y métodos para provocar una respuesta inmune antitumoral
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
EP2471548A1 (de) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
CN102552891A (zh) * 2011-12-27 2012-07-11 陆华 热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
ES2897579T3 (es) 2013-06-10 2022-03-01 Dana Farber Cancer Inst Inc Métodos y composiciones para reducir la inmunosupresión por células tumorales
US10145908B2 (en) 2013-07-19 2018-12-04 Allegro Microsystems, Llc Method and apparatus for magnetic sensor producing a changing magnetic field
EP3254701A1 (en) 2016-06-09 2017-12-13 IMBA-Institut für Molekulare Biotechnologie GmbH Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections
US20180273903A1 (en) * 2016-12-30 2018-09-27 Celularity, Inc. Genetically modified natural killer cells
CN111344402A (zh) * 2017-12-14 2020-06-26 Ezy生物科技有限公司 受试者特异性肿瘤抑制细胞及其用途
CA3115526A1 (en) 2018-10-15 2020-04-23 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
KR20210149757A (ko) * 2019-04-09 2021-12-09 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도
CN114206855A (zh) * 2019-05-17 2022-03-18 紐力克斯治疗公司 用于Cbl-b抑制的氰基环丁基类化合物及其用途
JP2022542323A (ja) * 2019-07-30 2022-09-30 ニューリックス セラピューティクス，インコーポレイテッド Ｃｂｌ－ｂの阻害のための尿素、アミド、および置換されたヘテロアリール化合物
JP2022549007A (ja) 2019-09-24 2022-11-22 ニューリックス セラピューティクス，インコーポレイテッド 養子細胞療法に使用するためのｃｂｌ阻害剤および組成物
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
CN115554290A (zh) * 2021-07-01 2023-01-03 中国科学院分子细胞科学卓越创新中心 五羟色胺或其受体激动剂在治疗ilc2细胞介导的免疫性疾病中的应用
EP4289939A1 (en) 2022-06-10 2023-12-13 Apeiron Biologics AG Population of transfected immune cells and method for their production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037989A1 (en) * 2001-08-27 2005-02-17 Lewis David L. Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
ES2359055T3 (es) * 2002-09-11 2011-05-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y el tratamiento de tumores.
WO2004078130A2 (en) 2003-03-03 2004-09-16 Proteologics, Inc. Posh interacting proteins and related methods
US20070054355A1 (en) 2003-03-05 2007-03-08 Yuval Reiss Cbl-b polypeptides, complexes and related methods
EP1651226B1 (en) * 2003-07-11 2010-02-24 Proteologics, Inc. Ubiquitin ligase inhibitors and methods related thereto
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
WO2005044840A2 (en) * 2003-10-17 2005-05-19 The Cbr Institute For Biomedical Research, Inc. Modulation of anergy and methods for isolating anergy-modulating compounds
WO2005069791A2 (en) * 2004-01-08 2005-08-04 Cedars-Sinai Medical Center Compositions and methods for enhancing the th1 response in connection with dendritic cell vaccines
CA2574572A1 (en) * 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
US7868159B2 (en) 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
TWI368637B (en) * 2005-09-05 2012-07-21 Hon Hai Prec Ind Co Ltd High lustrous nano paint and methods for manufacturing and using the same
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
ES2566502T3 (es) * 2006-09-13 2016-04-13 The Trustees Of Columbia University In The City Of New York Agentes y métodos para provocar una respuesta inmune antitumoral
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität

Also Published As

Publication number Publication date
IL206155A0 (en) 2010-12-30
CY1120136T1 (el) 2018-12-12
BRPI0821003A2 (pt) 2015-06-16
KR101692797B1 (ko) 2017-01-05
EP2220214B1 (de) 2018-01-17
CA2708343C (en) 2018-09-04
BRPI0821003B1 (pt) 2019-03-26
DK2220214T3 (en) 2018-04-16
BRPI0821003B8 (pt) 2021-05-25
PT2220214T (pt) 2018-04-23
IL206155A (en) 2014-07-31
CN101918544A (zh) 2010-12-15
CA2708343A1 (en) 2009-06-18
LT2220214T (lt) 2018-03-26
HUE037235T2 (hu) 2018-08-28
CN101918544B (zh) 2014-03-19
JP6118491B2 (ja) 2017-04-19
JP6175103B2 (ja) 2017-08-02
CN103898051B (zh) 2019-07-26
WO2009073905A2 (de) 2009-06-18
WO2009073905A8 (de) 2009-09-03
CN103898051A (zh) 2014-07-02
ZA201003791B (en) 2011-03-30
ES2665928T3 (es) 2018-04-30
AU2008336276B2 (en) 2014-06-12
NZ585646A (en) 2012-05-25
JP2011507806A (ja) 2011-03-10
KR20100110779A (ko) 2010-10-13
HRP20180558T1 (hr) 2018-06-01
WO2009073905A3 (de) 2009-10-22
AU2008336276C1 (en) 2015-01-15
EP3363892A1 (de) 2018-08-22
EP2220214A2 (de) 2010-08-25
AT506041A1 (de) 2009-05-15
AU2008336276A1 (en) 2009-06-18
EA201000974A1 (ru) 2010-12-30
US20100260808A1 (en) 2010-10-14
US8809288B2 (en) 2014-08-19
RS56941B1 (sr) 2018-05-31
MX2010006296A (es) 2011-02-23
SI2220214T1 (en) 2018-04-30
JP2015231371A (ja) 2015-12-24
EA018966B1 (ru) 2013-12-30

Similar Documents

Publication Publication Date Title
HRP20180558T1 (hr) Postupak za povećavanje imunosnog reaktiviteta
GB0712395D0 (en) Method
GB0707096D0 (en) Method
PL2365938T3 (pl) Sposób odsiarczania
EP2171169A4 (en) METHOD
PT2096102E (pt) Processo para a produção de metileno-difenil-diisocianatos
GB0714442D0 (en) Method
HRP20150775T1 (en) Method for preparing hypoallergens
GB0703366D0 (en) Method
GB2456999B (en) Method for preparing 2-deoxy-L-ribose
GB0710321D0 (en) Method
TWI346904B (en) Method for making decision
GB0714338D0 (en) method
GB0711843D0 (en) Method
GB0705321D0 (en) Method
EP2053054A4 (en) PROCESS FOR INTRODUCING A NUCLEIC ACID PROTECTION GROUP
GB0710519D0 (en) Method
EP2325161A4 (en) METHOD FOR PRODUCING A HYDROXYESTER COMPOUND
GB0714239D0 (en) Method
GB0714135D0 (en) Method
GB0710520D0 (en) Method
GB0706833D0 (en) Method
GB0710518D0 (en) Method
GB0710398D0 (en) Method
PL381143A1 (pl) Sposób otrzymywania 2-metyloglicydolu